FindTrial
Sign In

A STUDY ON FAT CONTENT OF LIVER IN NON ALCOHOLICS AND LIVER STIFFNES

A study on predictive factors of NAFLD and severity of fibrosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/04/024763
Enrollment
200
Registered
2020-04-21
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K740- Hepatic fibrosis

Interventions

Intervention1: FIBROSCAN: A FIBROSCAN IS A FORM OF ULTRASOUND THAT MEASURES LIVER STIFNESS Control Intervention1: NOT APPLICABLE: NOT APPLICABLE

Sponsors

DR SHIRAN SHETTY
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ALL PATIENTS WHOSE ULTRASOUND IS SHOWING FATTY LIVER

Exclusion criteria

Exclusion criteria: 1.PATIENTS WITH HISTORY OF SIGNIFICANT ALCOHOL INTAKE 2.PATIENTS WITH KNOWN LIVER DISEASE LIKE,WILSONS DISEASE ,HEMOCHROMATOSIS OR OTHER AUTOIMMUNE DISEASE

Design outcomes

Primary

MeasureTime frame
TG/HDL RATIO CAN BE USED TO PREDICT NAFLD HIGH BARD SCORE AND HIGH APRI CORRELATES WELL WITH SEVERITY OF FIBROSIS IN NAFLD Timepoint: OUTCOME IS ASSESED AT THE END OF STUDY—

Secondary

MeasureTime frame
TG/HDL RATIO CAN BE USED TO PREDICT NAFLDTimepoint: ASSESMENT IS DONE AT THE END OF STUDY—

Countries

India

Contacts

Public ContactDRSASHIKALA

kasturba medical college ,manipal

ram.bhat@manipal.edu9945272251

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026